Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
01 mai 2024 16h15 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
30 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Poster Presentation at American Association for Cancer Research:
18 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment...
Panbela Announces Transfer to OTCQB Market
16 avr. 2024 17h29 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 mars 2024 16h10 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
12 mars 2024 16h15 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
15 févr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Closing of Approximately $9.0 Million Public Offering
01 févr. 2024 07h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
30 janv. 2024 08h15 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...